Definium Therapeutics (DFTX) Total Current Liabilities (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Total Current Liabilities data on file, last reported at $81.1 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 166.11% year-over-year to $81.1 million in Q1 2026; TTM through Mar 2026 was $81.1 million, a 166.11% increase from a year earlier, with the FY2025 full-year figure at $66.7 million, up 71.69% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $81.1 million, up from $66.7 million in the prior quarter.
• Over the last five years, Total Current Liabilities for DFTX reached as high as $81.1 million in Q1 2026 and fell as low as $7.9 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $38.0 million across 5 years, with a median of $33.3 million in 2024.
• Across the five-year window, Total Current Liabilities soared 346.21% in 2023 and tumbled 53.3% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $17.9 million in 2022, then jumped by 80.23% to $32.2 million in 2023, then increased by 20.48% to $38.8 million in 2024, then surged by 71.69% to $66.7 million in 2025, then advanced by 21.61% to $81.1 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $81.1 million in Q1 2026, $66.7 million in Q4 2025, and $65.4 million in Q3 2025.